Gu Xiaodong, Hou Jingyuan, Weng Ruiqiang, Rao Jiawei, Liu Sudong
Meizhou Clinical Institute, Shantou University Medical College, Meizhou, China.
Research Experimental Center, Meizhou People's Hospital (Huangtang Hospital), Meizhou, China.
Immun Inflamm Dis. 2024 Dec;12(12):e70088. doi: 10.1002/iid3.70088.
Acute myocardial infarction (AMI) stands as a leading cause of global morbidity and mortality. This study aims to explore the potential roles of circulating exosomal lncRNA MALAT1 and LNC_000226 in AMI diagnosis and prognosis.
This retrospective observational study included 90 patients with AMI and 88 patients with normal coronary artery (NCA). Plasma exosomes were isolated via ultracentrifugation, and the levels of exosomal lncRNA MALAT1 and LNC_000226 were examined using qRT-PCR. Major adverse cardiovascular events (MACEs) that occurred during 1-year follow-up post-stent implantation were collected. The diagnostic value of exosomal MALAT1 and LNC_000226 was determined by receiver operating characteristic (ROC) analysis. The association between exosomal LNC_000226 and MACEs was assessed by Kaplan-Meier and Cox regression analysis.
Both lncRNA MALAT1 and LNC_000226 levels in plasma exosomes were elevated in AMI patients compared to NCA controls. Moreover, LNC_000226 (AUC: 0.889, sensitivity: 82%, specificity: 72%) exhibited superior diagnostic performance compared to MALAT1 (AUC: 0.707, sensitivity: 71%, specificity: 57%). During 1-year follow-up period, the incidence of MACEs was significantly higher among patients with high exosomal LNC_000226 levels compared to those with low exosomal LNC_000226 levels [64% (29/45) vs. 40% (18/45), p < 0.05]. Multivariable Cox regression analysis revealed a positive association between exosomal LNC_000226 level and the risk of MACEs in AMI patients (HR: 1.959, 95% CI: 1.040-3.689).
Circulating exosomal lncRNA MALAT1 and LNC_000226 are promising biomarkers for diagnosing AMI, with LNC_000226 potentially indicating a prognosis.
急性心肌梗死（AMI）是全球发病和死亡的主要原因。本研究旨在探讨循环外泌体长链非编码RNA MALAT1和LNC_000226在AMI诊断和预后中的潜在作用。
这项回顾性观察研究纳入了90例AMI患者和88例冠状动脉正常（NCA）患者。通过超速离心分离血浆外泌体，使用qRT-PCR检测外泌体长链非编码RNA MALAT1和LNC_000226的水平。收集支架植入后1年随访期间发生的主要不良心血管事件（MACE）。通过受试者工作特征（ROC）分析确定外泌体MALAT1和LNC_000226的诊断价值。通过Kaplan-Meier和Cox回归分析评估外泌体LNC_000226与MACE之间的关联。
与NCA对照组相比，AMI患者血浆外泌体中的lncRNA MALAT1和LNC_000226水平均升高。此外，LNC_000226（AUC：0.889，敏感性：82%，特异性：72%）与MALAT1（AUC：0.707，敏感性：71%，特异性：57%）相比，表现出更好的诊断性能。在1年随访期间，外泌体LNC_000226水平高的患者中MACE的发生率明显高于外泌体LNC_000226水平低的患者[64%（29/45）对40%（18/45），p<0.05]。多变量Cox回归分析显示，外泌体LNC_000226水平与AMI患者发生MACE的风险呈正相关（HR：1.959，95%CI：1.040-3.689）。
循环外泌体长链非编码RNA MALAT1和LNC_000226是诊断AMI的有前景的生物标志物，LNC_000226可能预示预后。
